enGene Holdings Inc.
enGene Holdings Inc.（ENGN）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · ENGN · 截至 2025年9月30日
股东结构概览
38
机构持有人数
▲ 1 vs Q2
$279.13M
机构持仓总市值
▲ $132.00M vs Q2
51.19M
总流通股
freeFloat 42.03%
40.87M
13F 申报持股数
▲ 448,012 vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
ENGN 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
FCPM III SERVICES B.V. biological products, (no diagnostic substances) | 9.63M | 18.85% | 18.85% | $65.79B | Nov 14, 2025 | — held |
VR ADVISER, LLC biological products, (no diagnostic substances) | 5.05M | 9.88% | 9.88% | $34.47B | Nov 14, 2025 | — held |
KYNAM CAPITAL MANAGEMENT, LP biological products, (no diagnostic substances) | 4.99M | 9.77% | 9.77% | $34.11B | Nov 14, 2025 | — held |
BLUE OWL CAPITAL HOLDINGS LP biological products, (no diagnostic substances) | 3.28M | 6.42% | 6.42% | $22.39B | Nov 12, 2025 | ▼ 450.0K |
CORMORANT ASSET MANAGEMENT, LP biological products, (no diagnostic substances) | 2.32M | 4.55% | 4.55% | $15.87B | Nov 14, 2025 | — held |
BRAIDWELL LP biological products, (no diagnostic substances) | 2.27M | 4.44% | 4.44% | $15.48B | Nov 14, 2025 | NEW |
DEEP TRACK CAPITAL, LP biological products, (no diagnostic substances) | 2.24M | 4.38% | 4.38% | $15.29B | Nov 14, 2025 | ▼ 2.32M |
PERCEPTIVE ADVISORS LLC biological products, (no diagnostic substances) | 2.10M | 4.10% | 4.10% | $14.32B | Nov 14, 2025 | NEW |
POINT72 ASSET MANAGEMENT, L.P. biological products, (no diagnostic substances) | 1.21M | 2.36% | 2.36% | $8.25B | Nov 14, 2025 | ▲ 100 |
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. biological products, (no diagnostic substances) | 1.16M | 2.27% | 2.27% | $7.90B | Nov 14, 2025 | NEW |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
7
增持
+148.1K 股7
新建仓
首次建仓8
减持
−5.04M 股6
清仓
完全退出净股数变化（前50家）
4.89M
+148.1K / −5.04M
净新增持仓人
+0
新建 7 个 / 退出 6 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
ENGN 内幕交易记录
数据来源：SEC Form 4
6
买入笔数
0
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
CHEUNG ANTHONY TZEYEW Chief Scientific Officer | Jan 30, 2026 | Award | 195,000 | $9.53 | $1.86M | 195.0K | Form 4 ↗ |
Giguere Lee Chief Legal Ofc. and Corp Secy | Jan 30, 2026 | Award | 195,000 | $9.53 | $1.86M | 195.0K | Form 4 ↗ |
Nichols Alexander Julian Chief Strategy & Ops. Ofc | Jan 30, 2026 | Award | 195,000 | $9.53 | $1.86M | 195.0K | Form 4 ↗ |
Daws D. Ryan Chief Financial Officer | Jan 30, 2026 | Award | 220,000 | $9.53 | $2.10M | 220.0K | Form 4 ↗ |
Cooper Ronald Harold Wilfred CEO & President | Jan 30, 2026 | Award | 801,000 | $9.53 | $7.63M | 801.0K | Form 4 ↗ |
Connolly Joan Chief Technology Officer | Jan 30, 2026 | Award | 195,000 | $9.53 | $1.86M | 195.0K | Form 4 ↗ |
Boyd Matthew Ross Chief Regulatory Officer | Jan 30, 2026 | Award | 195,000 | $9.53 | $1.86M | 195.0K | Form 4 ↗ |
Buck Jill Chief Development Officer | Jan 30, 2026 | Award | 195,000 | $9.53 | $1.86M | 195.0K | Form 4 ↗ |
Sweiti Hussein Chief Medical Officer | Sep 30, 2025 | Award | 600,000 | $6.83 | $4.10M | 600.0K | Form 4 ↗ |
Boyd Matthew Ross Chief Regulatory Officer | Jul 8, 2025 | Award | 100,000 | $3.83 | $383.0K | 100.0K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
enGene Holdings Inc.（ENGN）主要由机构投资者持有，机构持股比例约为 79.8%。公司内部人员持股约 57.97%，散户及公众持股约占剩余的 0.00%。
enGene Holdings Inc. 最大机构股东为 FCPM III SERVICES B.V.，截至 September 30, 2025 持有约 9.63 million 股，占总流通股的 18.85%。
目前共有 38 家机构持有 ENGN 股票，合计持仓市值约 $279,131,773，数据来源为最新 SEC 13F 申报。
常见问题
ENGN ownershipenGene Holdings Inc.（ENGN）主要由机构投资者持有，机构持股约 79.8%。最大股东为 FCPM III SERVICES B.V.，持股比例 18.85%。内部人员持股约 57.97%。数据来源 SEC Form 13F，截至 September 30, 2025。